Lung cancer is by far the leading cause of
cancer-related death. In 2002, an estimated 183,200 patients will be diagnosed
with lung cancer, and an estimated 161,400 deaths will occur. Much work
remains to be done in this disease, which is associated with a 5-year survival
of only 15.8%, and a median survival for stage IV disease (even with enhanced
cytotoxic therapies used in combination) ranging from 7.4 to 9.2 months.[1-6]
However, it should be noted that over the past 15 years, combination
platinum-based cytotoxic chemotherapy has resulted in a doubling of the median
survival rate among stage IV NSCLC patients, from approximately 4 to
8 months. Furthermore, an almost threefold increase in the 1-year survival
rate (from 11% to 14% up to 30% to 35%) and meaningful 2-year survival rates
have been demonstrated in several randomized trials.
Docetaxel (Taxotere) has demonstrated modest but very real survival and
quality-of-life advantages when used in the second-line NSCLC setting; it could
ultimately produce a more meaningful survival advantage in early- to
intermediate-stage disease.[8,9] This theory was evaluated in a phase II trial
conducted by the Southwestern Oncology Group (SWOG) in which patients received
docetaxel after completing concurrent chemoradiation therapy with cisplatin and
etoposide. The patients, all of whom had stage IIIB NSCLC without a malignant
pleural effusion, demonstrated a median overall survival of 27 months and a
3-year survival of 37%. The results of this phase II
multi-institutional, cooperative group study highlight the fact that agents that
have activity in advanced, refractory cancers often show significantly more
activity in earlier stages of disease. Therefore, docetaxel should be
investigated as a single agent and in combination with other cytotoxic agents,
as a building block to improve upon the results now possible in the treatment of
patients with NSCLC.
Numerous phase I and II trials have shown that single-agent docetaxel is
active in the treatment of incurable or metastatic NSCLC in chemotherapy-naive
patients. A combined overall response rate of 27% was documented in six phase II
trials of docetaxel, 100 mg/m² every 3 weeks, in this patient population, with a
median response duration of 6 months, a median overall survival of 9.2 months,
and a 1-year survival of 39%. Lower doses of docetaxel have also been
investigated in phase II trials in the front-line therapy of NSCLC. Docetaxel at
75 mg/m² and 60 mg/m² every 3 weeks resulted in overall response rates of 25%
and 19%, respectively, and median survivals of 10 and 9.2 months.[12,13]
Based on these findings, Roszkowski et al conducted a randomized, open-label
phase III trial in 207 patients with either unresectable or metastatic NSCLC who
were treated with docetaxel plus best supportive care (BSC) or BSC alone.
Patients in the chemotherapy arm received docetaxel at 100 mg/m² as a 1-hour
intravenous infusion every 21 days until evidence of disease progression,
the estimated maximal benefits from treatment were obtained, or unacceptable
toxicity. The study was conducted with 2-to-1 randomization; 137 patients
received docetaxel and 73 received BSC.
Overall survival was significantly longer for the docetaxel plus BSC arm as
compared to the BSC alone arm (P = .026). The 2-year survival in the docetaxel
plus BSC arm was 12%, whereas none of the patients in the BSC arm survived
longer than 20 months. The overall response rate in the patients who
received a minimum of two cycles of docetaxel was 19.7%. Time to disease
progression was significantly better in the docetaxel plus BSC arm vs the BSC
alone arm at 12.6 weeks vs 8.9 weeks, respectively (P < .001).
Quality-of-life tests revealed the superiority of the docetaxel arm (P = .0401).
Additionally, requirements for narcotic analgesics and palliative radiation
therapy were significantly lower in the docetaxel plus BSC arm vs the BSC alone
arm, in spite of the fact that 16% of the BSC arm went on to receive
Weekly Docetaxel Regimen
A trial of single-agent docetaxel as a weekly regimen in the treatment of
patients with NSCLC has been reported by Hainsworth et al. Docetaxel was
administered at 36 mg/m²/wk for 6 consecutive weeks of an 8-week cycle to
39 elderly or poor performance status patients with chemotherapy-naive NSCLC. An
overall response rate of 18% was demonstrated, with one complete response and
six partial responses. The median survival was 5 months, with an estimated 1
year survival rate of 27% in this group of elderly patients. Similar to findings
from other studies of weekly docetaxel administration, hematologic toxicities
were greatly reduced. Grade 3 leukopenia was noted in only three patients, with
none developing grade 4 myelosuppression.
As a result of these findings, and in particular in light of the absence of
grade 3/4 neutropenia or neuropathy, many community physicians favor using a
weekly schedule of docetaxel administration. Further testing remains to be
completed to determine whether response rates and survival are equivalent to the
every-3-week regimen. As will be discussed below, the use of docetaxel on a
weekly schedule also offers attractive options for the development of
Docetaxel and Cisplatin
Based on docetaxel’s single-agent activity as first- and second-line
therapy of NSCLC, and because the platinum compounds have long been a staple of
front-line therapy for NSCLC, the next logical step was to combine docetaxel
with cisplatin or carboplatin (Paraplatin). The lack of cross-resistance and the
largely nonoverlapping toxicity profile of docetaxel and the platinum agents
provided additional rationale to investigate the combinations.
Several phase I trials of docetaxel and cisplatin have established the
toxicity profile and activity of the combination in advanced NSCLC.[16-18] The
two maximum tolerated doses achieved were either docetaxel at 100 mg/m²
administered as a 1-hour infusion followed by cisplatin at 75 mg/m² 3-hour
infusion or docetaxel at 75 mg/m² as a 1-hour infusion followed by cisplatin at
100 mg/m² as a 3-hour infusion with cycles repeated every 3 weeks. Many
phase II trials have used doses of 75 mg/m² of each of the two compounds
administered at 3-week intervals; however, other regimens have also been
explored, as discussed below.
The Zalcberg et al TrialZalcberg treated a total of 47 chemo-naive
patients with the combination of docetaxel at 75 mg/m² followed by cisplatin at
75 mg/m². Premedications included ondansetron (Zofran), dexamethasone,
promethazine, and standard hyperhydration with magnesium supplementation. Of the
47 patients (72% male) enrolled, two-thirds had metastatic disease and 85% had a
good performance status (World Health Organization [WHO] 0 or 1). All 47
patients were assessable for toxicity and 37 were evaluable for response, with 3
patients ineligible for enrollment and 8 discontinuing treatment due to
Among assessable patients, the overall response rate was 38.9% (95%
confidence interval [CI]: 23.1% to 56.5%). An additional 36.1% had stable
disease and 25% had disease progression. Based on an intent-to-treat analysis,
the objective response rate was 29.8%, with a median survival of 9.6 months and
an estimated 1-year survival of 33%. The most significant toxicities seen
included grade 3/4 nausea (26%), hypertension (15%), diarrhea (15%), and
dyspnea (13%). However, only one patient (1.2%) experienced grade 3 neurosensory
toxicity after completing eight cycles of therapy. Other grade 3/4 toxicities
included hypomagnesemia (24%), febrile neutropenia (13%), and neutropenic
infections (11%), leading to two treatment-related deaths. The authors concluded
that docetaxel/cisplatin is active and feasible as a front-line therapy for
NSCLC, with a favorable response rate, an acceptable toxicity profile, and good
median and 1-year survivals.
The Le Chevalier et al Trial
Le Chevalier et al evaluated docetaxel, 75 mg/m², plus cisplatin, 100 mg/m², administered every 3 weeks for three
cycles and then every 6 weeks in 51 chemotherapy-naive patients with locally
advanced or metastatic (80%) NSCLC, including 37% with bone involvement. The
patient population was largely male (92%), with a median age of 54 years, and a
median WHO performance status of 1. Patients received a median of four treatment
cycles (range: 1 to 9), with more than 90% receiving full doses of both drugs as
planned per protocol.
An overall response rate of 33% (95% CI: 19.6%-49.6%), was demonstrated
among the 42 evaluable patients, 14 of whom responded. The median response
duration was 7.3 months, with a median survival of 8.4 months and a 1-year
survival of 35%. Neutropenia was the predominant toxicity, occurring in
approximately two-thirds of patients, with febrile neutropenia reported in seven
patients (14%) and sepsis in one. Nonhematologic toxicities included grade 3
vomiting (14%), although neuromotor and neurosensory deficits were infrequent,
with grade 3 neuromotor and neurosensory toxicities occurring in one
patient each (2%).
The authors concluded that the results were encouraging, given the poor
prognostic factors of the patient population, but questioned whether cisplatin
added to the efficacy of single-agent docetaxel, given its impressive cumulative
phase II response rate of 27% in a similar patient population.
The Belani et al Trial
The third multicenter trial was conducted by
Belani et al, who tested a combination of docetaxel at 75 mg/m² and cisplatin at
75 mg/m² every 3 weeks in 47 patients with stage IIIB or IV NSCLC. Among the
40 patients evaluable for response, 1 achieved a complete response and 14
achieved a partial response, for an overall response rate of 37.5%
(intent-to-treat response rate: 32%). The median duration of response was 34.6
weeks. The median duration of survival was 11.3 months, and the median time to
progression was 18.9 weeks. As demonstrated previously, grade 3/4 neutropenia
was predominant, reported in 74.4% of patients and in 55.4% of cycles. The
incidence of febrile neutropenia was 12.8%. Nonhematologic toxicities included
asthenia in 14.9% of patients. Other grade 3/4 toxicities included nausea (20%),
vomiting (12.5%), neurosensory effects (15%), neuromotor effects (12.5%),
diarrhea (10%), and infection (7.5%). The Belani trial was the third phase II
trial to demonstrate the substantial activity of the docetaxel/cisplatin
The Georgoulias et al Trial
The fourth phase II trial of the
docetaxel/cisplatin combination was conducted by Georgoulias et al, who
performed a multicenter investigation of the regimen in 53 chemotherapy-naive
patients with stage IIIB/IV NSCLC. Eligible patients received docetaxel at 100 mg/m²
on day 1 and cisplatin at 80 mg/m² on day 2 every 21 days. Prophylactic
granulocyte colony-stimulating factor (G-CSF, Neupogen), 150 µg/m², was
administered on days 3 to 13. An overall response rate of 45% was
documented, with 1 complete response and 23 partial responses. The median time
to progression was 36 weeks, and the median survival was 48 weeks. The 1-year
survival rate of 48% was notable.
Despite the use of prophylactic G-CSF, grade 3/4 neutropenia developed in 43%
of patients and resulted in febrile neutropenia in 28%. There were two septic
deaths reported in this study. Nonhematologic toxicities included grade 3
fatigue (13%), grade 3/4 diarrhea (11%), grade 3 neurotoxicity (9%), and grade
3/4 mucositis (7.5%). The authors concluded that although the
docetaxel/cisplatin combination was highly active at the doses used in this
study, the incidence of hematologic toxicity was high despite the prophylactic
use of G-CSF.
Several other trials of the docetaxel/cisplatin combination have been
reported in abstract form, with overall response rates ranging from 47% to
52%.[23-25] As a result of the encouraging response rates, time to progression,
and median survival rates consistently demonstrated in phase II studies, the
docetaxel/cisplatin combination has been investigated in large, phase III
randomized trials, the results of which will be discussed below.
1. Jemal, A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J
Clin 52:23-47, 2002.
2. Minna J, Sekido Y, Fong K, et al: Cancer of the lung, in DeVita VT,
Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 5th
ed, pp 849-911. Philadelphia, Lippincott, 1997.
3. Schottenfield D: Etiology and epidemiology of lung cancer, in Pass HI,
Mitchell JB, Johnson DH, et al (eds): Lung Cancer Principles and Practice, 2nd
ed, pp 367-388. Philadelphia, Lippincott Williams & Wilkins, 2000.
4. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in
patients with advanced non-small-cell lung cancerreport of a Canadian
multicenter randomized trial. J Clin Oncol 6:633-641, 1988.
5. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care vs supportive care
and combination chemotherapy in metastatic non-small-cell lung cancer. Does
chemotherapy make a difference? Cancer 63:1271-1278, 1989.
6. Cartei G, Cartei F, Cantone A, et al: Cisplatin-cyclophosphamide-mitomycin
combination chemotherapy with supportive care vs supportive care alone for
treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst
7. Johnson DH: Treatment strategies for metastatic non-small-cell lung
cancer. Clin Lung Cancer 1:34-41, 1999.
8. Shepherd F, Ramlau R, Mattson K, et al: Prospective randomized trial of
docetaxel vs best supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy. J Clin Oncol
9. Fossella FV, DeVore R, Kerr R, et al: Randomized phase III trial of
docetaxel vs vinorelbine or ifosfamide in patients with advanced non-small-cell
lung cancer previously treated platinum-based chemotherapy. J Clin Oncol
10. Gaspar L, Gandara D, Chansky K, et al: Consolidation docetaxel following
concurrent chemoradiotherapy in pathologic stage IIIb non-small-cell lung cancer
(NSCLC) (SWOG 9504): Patterns of failure and updated survival (abstract 1255).
Proc Am Soc Clin Oncol 20:315a, 2001.
11. Rigas JR: Single-agent docetaxel in previously untreated non-small-cell
lung cancer. Oncology 11(suppl 7):17-21, 1997.
12. Miller VA, Rigas JR, Kris MG, et al: Phase II trial of a 75 mg/m² dose of
docetaxel with prednisone premedication for patients with advanced
non-small-cell lung cancer. Cancer 75:968-972, 1995.
13. Kunitoh H, Watanade K, Onoshi T, et al: Phase II trial of docetaxel in
previously untreated advanced non-small-cell lung cancer: A Japanese cooperative
study. J Clin Oncol 14:1649-1655, 1996.
14. Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter,
randomized, phase III study of docetaxel plus best supportive care vs best
supportive care in chemotherapy-naïve patients with metastatic or
non-resectable localized non-small-cell lung cancer (NSCLC). Lung Cancer
15. Hainsworth JD, Burris HA, Litchy S, et al: Weekly docetaxel in the
treatment of elderly patients with advanced non-small-cell lung carcinoma. A
Minnie Pearl Cancer Research Network phase II trial. Cancer 89(2):328-333, 2000.
16. Cole JT, Gralla RJ, Marques CB, et al: Phase I/II study of cisplatin and
docetaxel in non-small-cell lung cancer (abstract 1087). Proc Am Soc Clin Oncol
17. Pronk LC, Schellens JHM, Planting AST, et al: Phase I and pharmacologic
study of docetaxel and cisplatin in patients with advanced tumors. J Clin Oncol
18. Millward MH, Yalcberg J, Bishop JF, et al: Phase I trial of docetaxel and
cisplatin in previously untreated patients with advanced non-small-cell lung
cancer. J Clin Oncol 15:750-758, 1997.
19. Zalcberg J, Millward M, et al: Phase II study of docetaxel and cisplatin
in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953, 1998.
20. Le Chevalier T., Monnier A, Douillard JY, et al: Docetaxel (Taxotere)
plus cisplatin: An active and well-tolerated combination in patients with
advanced non-small-cell lung cancer. Eur J Cancer 34:2032-2036, 1998.
21. Belani CP, Bonomi P, Dobbs TW, et al: Docetaxel and cisplatin in patients
with advanced non-small-cell lung cancer (NSCLC): A multicenter phase II trial.
Clin Lung Cancer 1(2):144-150, 1999.
22. Georgoulias V, Androulakis N, Dimopoulos AM, et al: First-line treatment
of advanced non-small-cell lung cancer with docetaxel and cisplatin: A
multicenter phase II study. Ann Oncol 9:331-334, 1998.
23. Faderl B, von Pawel J, Wagner H, et al: Phase II study of docetaxel and
cisplatin in a circadian timing as first-line chemotherapy in advanced
non-small-cell lung cancer (abstract 1017). Eur J Cancer 35:256, 1999.
24. Cole JT, Gralla RJ, Rittenberg CN, et al: Defining the dose of docetaxel
(Taxotere) in combination chemotherapy in non-small-cell lung cancer: Preserving
efficacy with lower dose regimens (abstract 1671). Proc Am Soc Clin Oncol
25. Androulakis N, Dimopoulos AM, Kourousis C, et al. First-line treatment of
advanced non-small cell lung cancer (NSCLC) with docetaxel and cisplatin: A
multicenter pahse II study (abstract 1655). Proc Am Soc Clin Oncol 16:461a,
26. Belani CP, Hadeed V, Ramanathan R, et al: Docetaxel and carboplatin: A
phase I and pharmacokinetic trial for advanced non-hematologic malignancies
(abstract 771). Proc Am Soc Clin Oncol 16:220a, 1997.
27. Belani C, Einzig A, et al: Multicenter phase II trial of docetaxel and
carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann
Oncol 11:673-678, 2000.
28. Harvey J, Windsor K, Lasker J: A phase II study of docetaxel and
carboplain in patients with advanced non-small-cell lung cancer (NSCLC)
(abstract 2000). Proc Am Soc Clin Oncol 19:511a, 2000.
29. Schuette W, Bork I, Wollschlager B, et al: Combination chemotherapy with
docetaxel and carboplatin for advanced non-small-lung cancer. Clin Drug Invest
30. Jahanzeb M, Sarna G, Hirsch R, et al: A multicenter phase II trial of
carboplatin and docetaxel in previously untreated advanced non-small-cell lung
carcinoma (NSCLC) (abstract 2011). Proc Am Soc Clin Oncol 19:514a, 2000.
31. Arcenas A, Karkera D, Krasnow S: A phase II trial of carboplatin and
docetaxel for stage IIIb/IV non-small-cell lung cancer (abstract 2848). Proc Am
Soc Clin Oncol 20: 2001.
32. Schiller JH, Harrington D, Belani C, et al: Comparison of four
chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med
33. Fossella F: Multicenter, randomized phase III study of taxotere +
cisplatin or taxotere + carboplatin vs vinorelbine plus cisplatin as first-line
therapy for advanced non-small-cell lung cancer (abstract 562). Eur J Cancer
37(suppl 6):S154, 2001.
34. Budman D, Lichtman S: Investigational drugs, in: Perry MC (ed): The
Chemotherapy Source Book, pp 479-555. Baltimore, Williams & Wilkins, 1997.
35. Spiridonidis CH, Laufman LR, Jones J, et al: Phase I study of docetaxel
dose escalation in combination with fixed weekly gemcitabine in patients with
advanced malignancies. J Clin Oncol 16:3866-3873, 1998.
36. Pawinski A, Louwerens M, Tonelli D, et al: A phase I study of docetaxel
and gemcitabine combination in chemotherapy-naïve patients with advanced or
metastatic non-small-cell lung cancer (abstract 957). Proc Am Soc Clin Oncol
37. Spiridonidis CH, Laufman L, Jones J, et al: Phase I study of docetaxel
dose-escalation in combination with fixed weekly gemcitabine in patients with
advanced malignancies. J Clin Oncol 16:3866-3873, 1998.
38. McKay CE, Hainsworth JD, Burris HA, et al: Weekly docetaxel/gemcitabine
in the treatment of elderly patients (pts) with advanced non-small-cell lung
cancer (NSCLC): A Minnie Pearl Cancer Research Network phase II trial (abstract
2793). Proc Am Soc Clin Oncol 20:260b, 2001.
39. Neubauer M, Garfield D, Khan M, et al: Phase II trial of weekly docetaxel
(Taxotere) plus gemcitabine (Gemzar) as first-line therapy for patients with
advanced non-small-cell lung cancer (abstract 2760). Proc Am Soc Clin Oncol
40. Jensen NV, Hansen O, rose C, et al: Combination of docetaxel and
gemcitabine in the treatment of advanced non-small-cell lung cancer (NSCLC)
(abstract 1026). Proc Eur Cancer Conf 10:S258, 1999.
41. Bhargava P, Marshall JL, Fried K, et al: Phase I and pharmacokinetic
study of two sequences of gemcitabine and docetaxel administered weekly to
patients with advanced cancer. Cancer Chemother Pharmacol 48:95-103, 2001.
42. Eckardt JR, Schmidt AM, Needles BM, et al: A phase I study of the
combination of docetaxel (D) and gemcitabine (G) (abstract 920). Proc Am Soc
Clin Oncol 17:240a, 1998.
43. Rigas JR, Rothenberg ML, Davis TH, et al: Phase I clinical and
pharmacokinetic study of docetaxel with two gemcitabine infusion schedules
(abstract 870). Proc Am Soc Clin Oncol 18:226a, 1999.
44. Denes AE, Needles BM, Schmidr A, et al: A comparison of two schedules of
docetaxel in combination with gemcitabine given every other week (abstract 828).
Proc Am Soc Clin Oncol 19:212a, 2000.
45. Georgoulias V, Kouroussis C, et al: Front-line treatment of advanced
non-small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase
II trial. J Clin Oncol 17:914-920, 1999.
46. Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and
non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A
randomised multicentre trial. Lancet 357:1478-84, 2001.
47. Miller V, Ng K, et al: Phase I trial of docetaxel and vinorelbine in
patients with advanced non-small-cell lung carcinoma. Cancer 88:1045-1050, 2000.
48. Miller V, Krug L, et al: Phase II trial of docetaxel and vinorelbine in
patients with advanced non-small-cell lung cancer. J Clin Oncol 18:1346-1350,
49. Kourousis C, Androulakis N, Kakolyris S, et al: First-line treatment of
advanced non-small-cell lung carcinoma with docetaxel and vinorelbine. Cancer
50. Bennouna J, Monnier A, Riviere A, et al: A phase II study of docetaxel
and vinorelbine combination chemotherapy in patients with advanced
non-small-cell lung cancer. Eur J Cancer 36(9):1107-1112, 2000.
51. Papadimitrakopoulou V, Lozada JA, Henderson T, et al: A phase II study of
vinorelbine and docetaxel in the treatment of advanced non-small-cell lung
cancer as front-line and second-line therapy (abstract 2789). Proc Am Soc Clin
Oncol 20:259b, 2001.
52. Masuda N, Shunichi N, Kudoh S, et al: Phase I and pharmacologic study of
docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol
53. Khuri FR, Herbst RS, Fossella FV: Emerging therapies in non-small-cell
lung cancer. Ann Oncol 12(6):739-744, 2001.